Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor

Incorrect Supplementary Material

In the published article, there was an error in Supplementary Material PDF file.

1.) In the Supplementary Material PDF file the heading is incorrect. Instead of “Allosteric” it should be “Competitive” as it is also stated in the title of the main article. The correct heading of the Supplementary Material PDF file is “Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor.”

2.) One author’s name has changed from Astrid Obrecht to Astrid Bülow. In addition, one authors is missing in the heading of the Supplementary Material PDF file. The author list should be Laura Grohs^1,2, Linhan Cheng¹, Saskia Cönen^1,3, Bassam G. Haddad³, Astrid Bülow^1,4, Idil Toklucu⁵, Lisa Ernst⁶, Jannis Körner^5,7, Günther Schmalzing¹, Angelika Lampert⁵, Jan-Philipp Machtens^1,3 and Ralf Hausmann^1*

The correct material statement appears below.

Heading of Supplementary Material PDF file:

“Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor.”

Laura Grohs^1,2, Linhan Cheng¹, Saskia Cönen^1,3, Bassam G. Haddad³, Astrid Bülow^1,4, Idil Toklucu⁵, Lisa Ernst⁶, Jannis Körner^5,7, Günther Schmalzing¹, Angelika Lampert⁵, Jan-Philipp Machtens^1,3 and Ralf Hausmann^1*

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Summary

Keywords

P2X3 receptor, nociception, chronic pain, non-steroidal anti-inflammatory drugs (NSAIDs), competitive antagonist, drug screening

Citation

Grohs L, Cheng L, Cönen S, Haddad BG, Bülow A, Toklucu I, Ernst L, Körner J, Schmalzing G, Lampert A, Machtens J-P and Hausmann R (2023) Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor. Front. Pharmacol. 14:1225522. doi: 10.3389/fphar.2023.1225522

Received

19 May 2023

Accepted

22 May 2023

Published

02 June 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

14 - 2023

Updates

Check for updates

Copyright

© 2023 Grohs, Cheng, Cönen, Haddad, Bülow, Toklucu, Ernst, Körner, Schmalzing, Lampert, Machtens and Hausmann.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ralf Hausmann, rhausmann@ukaachen.de

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.